Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
04 2021
Historique:
received: 07 10 2020
revised: 13 11 2020
accepted: 11 12 2020
pubmed: 12 1 2021
medline: 11 3 2022
entrez: 11 1 2021
Statut: ppublish

Résumé

Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of national rectal cancer IMRT guidance. A web-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment planning and treatment verification. A descriptive statistical analysis was carried out. In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease; target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily volumetric treatment verification were considered potentially feasible by most centres. This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT Guidance.

Identifiants

pubmed: 33423883
pii: S0936-6555(20)30492-1
doi: 10.1016/j.clon.2020.12.011
pmc: PMC7985673
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-223

Subventions

Organisme : Medical Research Council
ID : MC_PC_12001/2
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Références

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1003-1010
pubmed: 27727065
Cancer. 2001 Aug 15;92(4):896-902
pubmed: 11550163
Radiat Oncol J. 2018 Dec;36(4):276-284
pubmed: 30630266
Radiother Oncol. 2009 Aug;92(2):202-9
pubmed: 19454365
Am J Clin Oncol. 2008 Jun;31(3):264-70
pubmed: 18525306
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):29-36
pubmed: 26163334
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):188-197
pubmed: 27810119
Clin Oncol (R Coll Radiol). 2020 Jan;32(1):35-42
pubmed: 31362843
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1202-1211
pubmed: 29859793
J Cancer. 2017 Sep 6;8(16):3114-3121
pubmed: 29158782
Radiother Oncol. 2020 Jul;148:213-215
pubmed: 32342861
Clin Oncol (R Coll Radiol). 2016 Aug;28(8):522-31
pubmed: 26936609
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Lancet Oncol. 2017 Mar;18(3):336-346
pubmed: 28190762
Radiat Oncol. 2014 Mar 07;9:70
pubmed: 24606870
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1129-42
pubmed: 16750329
Clin Oncol (R Coll Radiol). 2016 Feb;28(2):93-102
pubmed: 26643092
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80
pubmed: 22763027
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Radiother Oncol. 2019 Sep;138:38-44
pubmed: 31136961
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Adv Radiat Oncol. 2017 Oct 12;3(1):34-41
pubmed: 29556578
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):97-102
pubmed: 21481722
Eur J Cancer. 2020 Mar;128:7-16
pubmed: 32109852

Auteurs

C R Hanna (CR)

CRUK Clinical Trials Unit, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, Glasgow, UK. Electronic address: Catherine.Hanna@glasgow.ac.uk.

F Slevin (F)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

A Appelt (A)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

M Beavon (M)

Royal College of Radiologists, London, UK.

R Adams (R)

Velindre Cancer Centre, Cardiff, UK.

C Arthur (C)

The Christie NHS Foundation Trust, Manchester, UK.

M Beasley (M)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

A Duffton (A)

CRUK Clinical Trials Unit, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, Glasgow, UK.

A Gilbert (A)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

S Gollins (S)

North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK.

M Harrison (M)

Mount Vernon Cancer Centre, Northwood, UK.

M A Hawkins (MA)

Medical Physics and Biochemical Engineering, University College London, London, UK.

K Laws (K)

Aberdeen Cancer Centre, Aberdeen Royal Infirmary, Aberdeen, UK.

S O'Cathail (S)

CRUK Clinical Trials Unit, University of Glasgow, Glasgow, UK; Beatson West of Scotland Cancer Centre, Glasgow, UK.

P Porcu (P)

Royal Free London NHS Foundation Trust, London, UK.

M Robinson (M)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

D Sebag-Montefiore (D)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

M Teo (M)

University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

S Teoh (S)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

R Muirhead (R)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH